Drug Search Results
More Filters [+]

CMAB-009

Alternative Names: cmab-009, cmab009, cmab 009
Latest Update: 2024-10-23
Latest Update Note: Clinical Trial Update

Product Description

novel recombinant human/mouse chimeric epidermal growth factor receptor (EGFR) monoclonal antibody

Mechanisms of Action: EGFR Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Shanghai Zhangjiang Biotechnology Limited Company
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CMAB-009

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Colorectal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

009mCRCIIIP

P3

Active, not recruiting

Colorectal Cancer

2022-05-06

34%

Recent News Events